Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation

Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation     

 

  

 

Absorb GT1 Bioresorbable Vascular Scaffold made by Abbot Vascular gained FDA Approval in July of 2016 subsequent to Premarket Approval Application (PMA: P150023)

Intended Use: The Absorb GT1 Bioresorbable Vascular Scaffold (BVS) is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.

FDA Communication Excerpt:

October 31, 2017 : The FDA is issuing this update to our March 18, 2017 letter to health care providers to inform the health care community that interim study results through three years from the pivotal clinical trial (ABSORB III) continue to show an increased rate of major adverse cardiac events and BVS scaffold thrombosis in patients receiving the Absorb GT1 Bioresorbable Vascular Scaffold (BVS), when compared to patients treated with the approved metallic XIENCE drug-eluting stent.

 

To Learn More About the Emerging Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation:   

The emerging GT1 Bioresorbable Vascular Scaffold Potential Litigation  will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

 

 

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Course attendees will receive the benefit of a step by step analysis of the emerging GT1 Bioresorbable Vascular Scaffold Potential using these primary metrics:

Mass Tort Nexus Metrics

 

 

 

 

 

 

 

 

 

 

 

 

Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including Annesley DeGaris>

 

 

The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

 

 

 


Share this Post: